Breaking AI & Tech News Analyzed

The Plant-Based Paradox: Growing Alternatives vs. Meat Dominance Should I tuck into a juicy steak or stick a tofu patty in a bun and call it a burger? Twenty years ago, that question was largely seen as a moral dilemma influenced by grim conditions in factory farms and slaughterhouses. Back then, animal rights activists were the loudest campaigners arguing for people to abstain from meat. They had limited success because vegetarians and vegans made up less than 5% of the population in rich countries – and the best fake meats were bland replicas of real flesh. The word flexitarian had not yet made it into the dictionary. The debate has shifted sharply. The pollution from animal agriculture, which makes up 12-20% of planet-heating gas, is now part of public discourse around eating meat. A dramatic rise in rates of obesity and diseases linked to red meat have made health concerns part of individual decisions to eat less of it. Meanwhile, some plant-based alternatives have improved in texture and taste to the point where even meat lovers struggle to tell that they did not come from an animal. The Rise of Plant-Based Alternatives: Market Transformation In one sense, there is a powerful story of personal action to tell. The tiny market share of vegetarians in the early 2000s provided the demand that companies needed to invest in making substitutes taste better. These alternatives are now helping meat eaters reduce their intake – an easier sell than convincing people to give it up entirely. Add that to a growing awareness about the environmental harm that livestock cause, and a rise in public support for stopping climate breakdown, and you have the ingredients for what could be a major societal shift away from damaging levels of meat-eating. Early signs of the trend are visible in countries such as Germany, a sausage-hungry nation where about one in 10 people are vegan or vegetarian and a further 37% describe themselves as flexitarian. Plant-based alternatives have become so common that a third of the population buy them regularly, a government survey found in November, and discount supermarkets have launched their own brands. Village cafes in far-right regions seem perfectly happy to serve oat milk with coffee. The Meat Consumption Data: Global Trends and Statistics The broader picture, though, is still dominated by animals. Data in a new report from the UN's Food and Agriculture Organisation suggests the average person eats six times as much chicken and twice as much pork as their grandparents did, with global meat supply having risen fourfold in the last 60 years. Much of the growth has taken place in poor countries in which better access to meat has helped counter hunger and malnutrition. But consumption is projected to keep rising, albeit at a slower rate, even in rich countries, where climate scientists and doctors recommend cutting down. Livestock are expected to contribute the vast majority of the projected 7.6% rise in global agricultural emissions over the next decade, at a time when global emissions from other parts of the economy, such as electricity generation, are set to fall. Industry Resistance and Consumer Behavior Patterns It is too early to tell whether the backlash signals a reversal or stalling of efforts to shift diets toward plants. In the UK, YouGov data shows the proportion of people who are vegetarians and vegans peaked in 2021 at 10% and has since fallen to 7%, while survey data in many other European countries suggests little change or even continued growth. The meat industry, meanwhile, is working hard to safeguard its dominance. In March, EU politicians voted to ban meaty names such as steak and bacon for plant-based alternatives. In the US, the "Make America Healthy Again" campaign from the Trump administration has enthusiastically promoted eating more meat, including many cow products such as beef tallow, going against medical advice. The pro-meat movement may also benefit from the protein obsession that has gripped rich countries, as well as growing fears about the health risks of ultra-processed food. Doctors are sceptical of the former – protein deficiencies in rich countries are rare, unlike fibre deficiencies – while there is little evidence to say much about the health impacts of processed plant-based products compared with processed meat ones. Future Outlook: Environmental and Health Implications The calculation is made more concerning by the indirect health impacts of meat-heavy diets, which stretch well beyond the risks to the person following them. Knock-on effects from the livestock industry range from stronger extreme weather events caused by climate breakdown to antimicrobial resistance that spreads superbugs. On Wednesday, an FAO report found that the use of antibiotics on livestock would rise by nearly a third in the next 15 years without government intervention, with potentially disastrous consequences for protection from disease. Health research is full of contradictory studies, and some advocates of meat-free diets have made sweeping claims that are not supported by the science. But what is clear, at a population level, is that people in rich countries are eating more meat and fewer plants than doctors consider healthy. And at a global level, the environmental harm from animal agriculture is likely to rise at a time when the planet needs it to fall.

GLP‑1 Medications Show Promise in Reducing Breast Cancer IncidenceRecent analyses presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago suggest that patients using GLP‑1 receptor agonists—a class of weight‑loss drugs—experienced a 30% lower likelihood of being diagnosed with breast cancer compared with non‑users.Study cohort: 110,000 women aged 45‑80.Risk reduction: 30% for breast cancer onset.Lead researcher: Dr Elizabeth McDonald, University of Pennsylvania.Adjunctive Use of GLP‑1 Drugs Cuts Breast Cancer MortalityA separate investigation involving 27,000 breast‑cancer patients in Italy reported that adding a GLP‑1 agent to standard therapy was associated with a 30% decrease in cancer‑related death.Institution: IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Meldola.Outcome: 30% lower mortality risk.Broad Cancer‑Spread Benefits Observed Across Multiple Tumor TypesData from the Cleveland Clinic, covering 12,000 patients with breast, lung, colorectal or liver cancer, indicated a 38‑50% reduction in progression to stage‑four disease among GLP‑1 users.Study size: 12,000 patients.Risk reduction range: 38%–50% for metastatic spread.Why These Findings Matter for Public Health and OncologyThe consistency of risk‑reduction signals across incidence, mortality and metastasis points to a potential paradigm shift: drugs originally designed for diabetes and obesity may become adjunct tools in cancer prevention and treatment. If confirmed, the impact could be substantial given the prevalence of obesity and the high incidence of breast cancer worldwide.Next Steps: Clinical Trials and Regulatory ConsiderationsExperts caution that the current evidence is observational. Ongoing randomized controlled trials will be needed to disentangle the effects of weight loss from direct pharmacologic actions of GLP‑1 agonists. Regulatory bodies may eventually evaluate these agents for oncologic indications, pending robust trial data.

Universal €1 Meal Initiative Expands Across French UniversitiesIn response to a survey showing that nearly half of France’s 3 million higher‑education students skip meals, the government announced this month that the previously means‑tested €1 meal will be available to every student.Government Extends €1 Meal to All Higher‑Education StudentsThe policy, previously limited to scholarship recipients, now covers all students at the 950 CNOUS‑run restaurants and cafeterias, including university sites such as Université Paris Dauphine and the Sorbonne’s Mabillon campus.Meal price: €1 for a three‑course balanced plate (starter, main, dessert).Optional extras: €0.55 per additional dish, coffee €0.60.Capacity: up to 2,400 students per sitting at Dauphine.Cost Implications: €120 million Funding and Pricing StructureThe state has earmarked €120 million for the programme in the next fiscal year, covering subsidies for the €1 price point while the regular tariff remains €3.30.Social and Health Impact on French Student PopulationOfficials argue the measure tackles food insecurity, public‑health concerns such as obesity, and promotes social cohesion by having all students share the same balanced meals.Student unions reported a rise in meal‑skipping from 45 % to 50 % before the policy.Positive feedback from students like Farid Rouba (chef) and Jérémy Reyes highlights satisfaction with quality and variety.Future Outlook: Sustainability and Potential AdjustmentsWhile the programme enjoys broad support, some students question the allocation of funds, suggesting resources could be redirected to cheaper accommodation. CNOUS plans to hire 200 extra staff and upgrade equipment to meet rising demand, but long‑term viability will depend on budgetary pressures and continued political backing.

Retatrutide Delivers Up to 28% Body‑Weight Reduction in Phase 3 StudyA new weight‑loss drug has helped participants in a sizable trial lose much more weight than other obesity drugs already on the market – up to an average of 28% of their body weight, Eli Lilly announced on Thursday. Phase 3 Trial Design and Dosing RegimenThe Indiana‑based company randomized 2,339 adults with obesity or overweight and at least one weight‑related comorbidity (no diabetes) to receive Retatrutide at 4 mg, 9 mg, 12 mg, or placebo for 80 weeks. The drug is a once‑weekly triple hormone receptor agonist targeting GLP‑1, GIP, and glucagon. Quantitative Outcomes and Safety ProfileAverage weight loss: 70.3 lb (28.3%) at the 12 mg dose.Average loss at 9 mg: 64.4 lb (25.9%).Average loss at 4 mg: 47.2 lb (19.0%).45.3% of 12 mg participants lost ≥30% of body weight.65.3% reduced BMI below 30; 37.5% of those starting with BMI ≥ 40 achieved this.Side‑effects increased with dose: nausea (28.6%‑42.4%), diarrhea (25.2%‑34.1%), vomiting (up to 25%).For comparison, Zepbound yields 15‑20% loss over 72 weeks and Wegovy 14‑19% over 64‑72 weeks. Implications for the Obesity‑Drug LandscapeThe magnitude of loss positions Retatrutide as the most effective pharmacologic option to date, potentially shifting prescriber preference away from existing GLP‑1 monotherapies. Its triple‑agonist mechanism adds glucagon, a hormone absent from current products, which may enhance metabolic control and appetite suppression. Future Outlook: Approval Path and Market PotentialAnalysts expect regulatory submissions within the next year, with a likely U.S. FDA review in 2027. If approved, Retatrutide could capture a sizable share of the rapidly expanding obesity‑treatment market, prompting competitors to explore multi‑agonist formulations.

Trump-Directed Trades Channel Hundreds of Millions into Eli LillyFinancial disclosures show that the Trump administration’s investment portfolio included multiple purchases of Eli Lilly shares, totalling between $220 million and $750 million in the first quarter of 2026. Seven separate acquisitions of Lilly stock, each up to $680,000, were made between 6 January and the end of March, aligning with new government programs that favour the company’s GLP‑1 weight‑loss drugs.Policy Moves Expand Access to GLP‑1 Obesity TreatmentsThe timing of the trades mirrors two key policy actions:CMS pilot program – The Centers for Medicare & Medicaid Services announced a pilot to broaden Medicare coverage for GLP‑1 medications, specifically Lilly’s Foundayo and Zepbound KwikPen.TrumpRx launch – In February, the White House unveiled TrumpRx, a direct‑to‑consumer drug‑sales platform that initially featured products from the first five manufacturers securing pricing deals, including Eli Lilly’s telemedicine service LillyDirect.Financial Scale of the Trades and Market ImpactTotal disclosed trades on Trump’s behalf in Q1 2026: several thousand across stocks and bonds.Estimated value range of all trades: $220 million–$750 million.Eli Lilly‑specific activity: seven purchases amounting to up to $680 k.Other high‑profile holdings disclosed: Apple, Boeing, Goldman Sachs, Meta, Microsoft, Nvidia.Implications for the Pharma‑Policy Nexus and Investor ScrutinyThe convergence of federal initiatives that directly benefit Eli Lilly’s GLP‑1 portfolio with simultaneous high‑value trades on the president’s behalf intensifies scrutiny over potential conflicts of interest. Critics argue that the disclosures highlight how policy decisions can create lucrative windows for politically‑linked investors, while the Trump Organization maintains that all investment decisions are made by independent third‑party managers.Future Outlook for Eli Lilly and Government‑Linked InvestingAnalysts anticipate heightened regulatory attention on disclosure practices and possible congressional inquiries into the timing of policy rollouts. If the GLP‑1 expansion continues, Eli Lilly could see sustained revenue growth, but any perception of preferential treatment may pressure the company’s stock and invite calls for stricter ethics rules governing presidential investment portfolios.

The Science Behind Cold Exposure and Weight Loss Wearing an ice vest or taking daily cold showers could help people lose weight, according to researchers. Despite the growing popularity of cold-water swimming and freezing plunges, to date there is minimal data on the health benefits of cold exposure. But a study of 47 adults with obesity or overweight has found that regular exposure to cold temperatures led to fat loss. The Study's Methodology and Findings Researchers at the University of Nottingham and the Leiden University Medical Center (LUMC) in the Netherlands gave half the participants an ice vest and waist wrap to wear for two hours every morning, while continuing their daily lives. The vests and waist wrap were worn on top of a thin T-shirt and contained gel-filled cooling packs that had been kept overnight in the freezer and maintained a temperature of 15C. In six weeks, participants lost 0.9kg (2lb), made up almost entirely of body fat, whereas the control group did not lose any weight and put on 0.6kg (1.3lb) on average. The Impact of Cold Exposure on Metabolism The lead researcher, Dr Mariëtte Boon, of LUMC, said: “This is one of the first studies looking at the impact of cold exposure over a prolonged period of time, involving people with overweight and obesity.” She added: “Vests like this can be worn at home and so cold exposure could be a simple and inexpensive addition to lifestyle strategies for weight loss such as healthy eating and physical activity.” The Potential for Cold Showers as a Weight Loss Tool The researchers, jointly funded by the Dutch Heart Foundation and the British Heart Foundation, are investigating whether other forms of regular cold exposure could reduce obesity, inflammation and prevent heart disease. The authors are conducting a separate study of 34 women in the Netherlands to see if cold showers also promote fat loss. Half of the women will have their shower on the coldest setting for 90 seconds every morning.

The Global Obesity Landscape: Not a Uniform EpidemicA continuing rise in obesity around the world is not inevitable, research suggests, with rates in some countries levelling off or potentially in decline. Researchers say focusing on what has been described as a global epidemic of obesity hides large variations in trends across different countries, sexes and age groups.Majid Ezzati, a professor of global environmental health at Imperial College London and author of the study, said: "I think the thing that's really important is this diversity exists even across countries that have really similar economic, environmental, technological features. So countries may look the same on the surface of it but obesity looks different."Comprehensive Analysis Reveals Complex PatternsWriting in the journal Nature, the international team, which involved a network of almost 2,000 researchers, described how for each country they calculated the change in the prevalence of obesity each year between 1980 and 2024. They drew on data from 4,050 population-based studies involving 232 million participants aged five years and above.They found that the prevalence of obesity increased in almost all countries over the 45-year period. However, in most high-income countries, a rapid rise in the prevalence of obesity has been replaced by a slower increase, a plateau, or a potential decline.Regional Variations in Obesity PrevalenceThe rate of growth in obesity is slowing in adults in the US and UK, reaching a prevalence of 40-43% and 27-30% respectively in 2024. Obesity is increasing steadily in Finland, has plateaued in Germany and may have started to decline in France, where 24-25%, 20-23% and 11-12% of adults respectively were thought to have the condition in 2024.Slowdowns were often seen in children and adolescents before adults. For the former group, the slowdown started as early as 1990 in Denmark and rates stabilised in most high-income countries by the mid-2000s. Obesity has plateaued in boys and girls in the UK, US, Germany and Japan at prevalences of 10-12%, 20-23%, 7-12% and 3-7% respectively.Meanwhile, obesity among young people and adults in many low-income and middle-income countries continues to rise and in some cases this is accelerating.Understanding the Drivers Behind Divergent TrendsThe team say it is important now to unpick what is behind the trends in different countries. The situation is complex: while there may be shared reasons for obesity, such easy access to unhealthy foods or a decrease in physical activity, the team say country-specific factors rooted in social, economic and policy considerations could also be important, from perceptions around body image to the presence or absence of interventions such as healthy school meals.Naveed Sattar, a professor of metabolic medicine at the University of Glasgow, who was not involved in the work, said the study highlighted how obesity trends were diverging sharply across countries. "English-speaking nations are doing particularly poorly, with the UK now among the countries with the highest obesity levels worldwide," he said.Sattar said it was encouraging that some countries appeared to have reached a plateau in obesity rates. "Understanding what has worked in those settings is crucial as it could help shape more effective public health strategies for the UK," he said, although he noted there could be country-specific aspects or customs at play.Future Outlook and Potential InterventionsHe said the rapid rise in obesity across many developing countries was especially concerning, not least as it could result in increases in diabetes and cardiovascular conditions.He added: "Looking ahead, it will be important to see how wider use of effective weight-loss medicines affects obesity trends, particularly in the UK and the United States. Recent signs of stabilisation in the USA suggest there may be room for cautious optimism. Combining evidence-based medicines with strong public health measures could begin to shift obesity rates in the right direction."

A new large‑scale randomized trial presented at the European Congress on Obesity in Istanbul indicates that the oral GLP‑1 antagonist orforglipron can help patients retain the majority of weight lost with injectable therapies such as tirzepatide (Mounjaro) and semaglutide (Wegovy).Trial Shows Oral Orforglipron Preserves Most Weight After Switching from InjectablesThe study, funded by Eli Lilly, followed 376 US patients who had been on tirzepatide or semaglutide injections for 72 weeks and then randomized them to a daily orforglipron tablet or placebo for an additional year.Participants were previously on weekly GLP‑1 jabs that typically produce 15‑20% body‑weight loss.After the injection phase, subjects were switched to oral therapy or placebo for 12 months.Primary endpoint: proportion of weight loss retained at 12 months.Quantitative Outcomes: 75% vs 49% Retention for Tirzepatide Users, 80% vs 38% for Semaglutide UsersWeight‑loss maintenance differed markedly between the pill and placebo groups:Tirzepatide cohort: 75% of lost weight retained with orforglipron vs 49% with placebo.Semaglutide cohort: 80% retained with the pill vs 38% with placebo.Secondary benefits—blood pressure, cholesterol, and glycaemic control—were also sustained in the pill arm.Implications for Obesity Management and Healthcare CostsExperts highlighted the broader significance:Dr Louis Aronne (Weill Cornell Medicine) emphasized that treating obesity directly can simultaneously improve glucose, lipid, and blood‑pressure metrics.Dr Marie Spreckley (University of Cambridge) noted patient preference for oral therapy due to convenience, storage, and lower cost.Dr Simon Cork (Anglia Ruskin University) warned that injectable GLP‑1 drugs, while highly effective, are expensive and limit long‑term accessibility for both private payers and the NHS.The findings suggest a potential shift toward oral agents that maintain efficacy while reducing financial and logistical burdens.Future Outlook: Oral GLP‑1 Therapies Could Redefine Chronic Obesity CareIf further trials confirm these results, orforglipron could become a cornerstone of chronic obesity management, enabling earlier intervention (BMI 25‑27) and possibly preventing progression to severe obesity.Regulators and payers will likely scrutinize cost‑effectiveness models, but the prospect of a cheap, daily tablet that sustains weight loss may reshape treatment algorithms worldwide.

Study Shows Fetal Exposure to Vegetable Flavours Influences Post‑Birth PreferencesThe research team gave pregnant volunteers powdered kale or carrot capsules during the third trimester and later measured their children’s facial reactions to the same smells. Reactions were recorded via ultrasound before birth, repeated at three weeks, and again when the children were about three years old.Methodology: Kale and Carrot Powder Capsules Administered to Expectant MothersParticipants were asked to swallow a capsule each day containing either kale or carrot powder. The study avoided large volumes of juice, which many volunteers found unpalatable, opting for a low‑cost capsule format.Capsules administered in late pregnancy (around 32 weeks gestation).Initial chemosensory response captured with ultrasound imaging.Follow‑up assessments at 3 weeks and 3 years post‑birth.Sample Size and Observed Reactions Reveal Early Flavor MemoryAlthough the cohort was modest, the findings were consistent:12 children were observed at age three.Infants exposed to carrot powder smiled when presented with a carrot scent and grimaced at kale, and vice‑versa for the kale group.The same preference pattern was evident in the ultrasound scans before birth.These results suggest that flavour exposure in utero can create a durable chemosensory memory.Potential Public‑Health Benefits of Early Dietary ConditioningIf replicated on a larger scale, the approach could offer a low‑cost strategy for improving population nutrition:Reducing childhood resistance to vegetables may lower long‑term risks of obesity and diet‑related diseases.Capsules are inexpensive and could be integrated into routine prenatal supplements.The concept is adaptable to different cultural diets, as noted by the researchers’ interest in fish‑rich Japanese diets.Next Steps: Larger Trials and Cross‑Cultural ApplicationsThe authors acknowledge the need for a bigger, funded study to confirm the effect across diverse populations. Future research aims to:Expand the sample size to hundreds of mother‑child pairs.Test additional flavours and odourants, including artificial sweeteners.Explore policy pathways for incorporating flavour‑exposure capsules into prenatal care guidelines.Published in Developmental Psychobiology, the paper titled “Do Human Fetuses Form Long‑Lasting Chemosensory Memories?” opens a new avenue for early nutritional interventions.